{"id":7909,"date":"2024-12-18T18:51:47","date_gmt":"2024-12-18T10:51:47","guid":{"rendered":"https:\/\/regask.com\/?p=7909"},"modified":"2024-12-18T18:51:47","modified_gmt":"2024-12-18T10:51:47","slug":"paraguay-dinavisa-arzneimittelzulassungsrichtlinie","status":"publish","type":"post","link":"https:\/\/regask.com\/de\/paraguay-dinavisa-drug-approval-guideline\/","title":{"rendered":"DINAVISA (Paraguay) genehmigt neue Richtlinie f\u00fcr gute Eva\u2026"},"content":{"rendered":"<p>Am 2. Dezember 2024 wird die <a href=\"https:\/\/regask.com\/de\/paraguay-vorschriften-fur-laktosefreie-lebensmittel\/\">Nationale Direktion f\u00fcr Gesundheits\u00fcberwachung<\/a> (DINAVISA) f\u00fchrte die <strong>\u201eLeitfaden f\u00fcr gute Bewertungspraktiken bei der Registrierung von Arzneimitteln.\u201c<\/strong> Diese Richtlinie stellt eine wichtige Aktualisierung des regulatorischen Rahmens dar und konzentriert sich auf die Gew\u00e4hrleistung der Qualit\u00e4t, Sicherheit und Wirksamkeit pharmazeutischer Produkte durch klare und transparente Bewertungsprozesse.<\/p>\n<p>Der Leitfaden zielt darauf ab, die Verfahren von DINAVISA an internationale Standards anzupassen und so die Harmonisierung mit globalen regulatorischen Normen zu f\u00f6rdern. Er gilt f\u00fcr alle pharmazeutischen Produkte, die f\u00fcr den menschlichen Gebrauch bestimmt sind, einschlie\u00dflich Arzneimittel, Biologika, Chemikalien, Reagenzien, Medizinprodukte und K\u00f6rperpflegeprodukte, die als Kosmetika oder Desinfektionsmittel klassifiziert sind.<\/p>\n<p>Zu den wichtigsten Punkten der Richtlinie z\u00e4hlen:<\/p>\n<ul>\n<li>Einhaltung von <strong>internationale Standards<\/strong> und bew\u00e4hrte Verfahren zur Arzneimittelbewertung.<\/li>\n<li>Detaillierte Compliance-Anforderungen f\u00fcr jede Phase der Produktentwicklung, einschlie\u00dflich pr\u00e4klinischer Studien, Genehmigung klinischer Tests, \u00c4nderungen nach der Markteinf\u00fchrung und Neuregistrierungsprozesse.<\/li>\n<li>Betonung auf einer <strong>multidisziplin\u00e4rer Ansatz<\/strong> das nicht-klinische, klinische, Biokompatibilit\u00e4ts-, Herstellungsprozess- und Risikomanagementbewertungen integriert.<\/li>\n<li>Mechanismen zur Nutzung von Bewertungen durch anerkannte <strong>internationale Regulierungsbeh\u00f6rden<\/strong> um \u00dcberpr\u00fcfungen zu beschleunigen und gleichzeitig strenge Sicherheits- und Wirksamkeitsstandards einzuhalten.<\/li>\n<li>Ein Schwerpunkt liegt auf der F\u00f6rderung <strong>kontinuierliche berufliche Weiterentwicklung<\/strong> und kritisches Denken bei den Gutachtern, um evidenzbasierte Entscheidungen auf der Grundlage des aktuellen wissenschaftlichen Verst\u00e4ndnisses sicherzustellen.<\/li>\n<\/ul>\n<p>Der neue Leitfaden ist ein wichtiger Schritt zur Modernisierung und Straffung des Arzneimittelzulassungsprozesses und stellt sicher, dass beh\u00f6rdliche Entscheidungen konsistent, transparent und an globale Praktiken angepasst sind.<\/p>\n<p>F\u00fcr weitere Einzelheiten oder Anfragen kontaktieren Sie uns bitte.<\/p>","protected":false},"excerpt":{"rendered":"<p>Am 2. Dezember 2024 ver\u00f6ffentlichte die Nationale Direktion f\u00fcr Gesundheits\u00fcberwachung (DINAVISA) den \u201cLeitfaden f\u00fcr gute Bewertungspraktiken bei der Registrierung von Arzneimitteln\u201d. Dieser Leitfaden stellt eine wichtige Aktualisierung des regulatorischen Rahmens dar und konzentriert sich auf die Gew\u00e4hrleistung der Qualit\u00e4t, Sicherheit und Wirksamkeit von Arzneimitteln durch klare und transparente Bewertungsprozesse. Der Leitfaden zielt darauf ab,\u2026<\/p>","protected":false},"author":30,"featured_media":7926,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[35,566],"tags":[496,609],"class_list":["post-7909","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pharma-biotech-latest-insights","category-paraguay-regulation","tag-market-authorization-regs","tag-guideline"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.3 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Paraguay Issues New Guideline for Drug Approvals | RegASK<\/title>\n<meta name=\"description\" content=\"Paraguay\u2019s DINAVISA releases a new guideline for drug approvals, aligning with global standards for safety and efficacy. Read more at RegASK\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/regask.com\/de\/paraguay-dinavisa-arzneimittelzulassungsrichtlinie\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"DINAVISA (Paraguay) Approves New Guideline for Good Evaluation Practices for Marketing Authorization\" \/>\n<meta property=\"og:description\" content=\"Paraguay\u2019s DINAVISA releases a new guideline for drug approvals, aligning with global standards for safety and efficacy. Read more at RegASK\" \/>\n<meta property=\"og:url\" content=\"https:\/\/regask.com\/de\/paraguay-dinavisa-arzneimittelzulassungsrichtlinie\/\" \/>\n<meta property=\"og:site_name\" content=\"RegASK\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-18T10:51:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/regask.com\/wp-content\/uploads\/2024\/12\/dinavisa-paraguay-approves-new-guideline-good-evaluation-practices-marketing-authorization.png\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Amandine Tricou\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:site\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Amandine Tricou\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/regask.com\\\/paraguay-dinavisa-drug-approval-guideline\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/paraguay-dinavisa-drug-approval-guideline\\\/\"},\"author\":{\"name\":\"Amandine Tricou\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/c2135b6dbdb95b0886564618fe9f4108\"},\"headline\":\"DINAVISA (Paraguay) Approves New Guideline for Good Eva&hellip;\",\"datePublished\":\"2024-12-18T10:51:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/paraguay-dinavisa-drug-approval-guideline\\\/\"},\"wordCount\":232,\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/paraguay-dinavisa-drug-approval-guideline\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/dinavisa-paraguay-approves-new-guideline-good-evaluation-practices-marketing-authorization.png\",\"keywords\":[\"Market authorization regs\",\"Guideline\"],\"articleSection\":[\"Pharma and Biotech\",\"Paraguay\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/regask.com\\\/paraguay-dinavisa-drug-approval-guideline\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/paraguay-dinavisa-drug-approval-guideline\\\/\",\"name\":\"Paraguay Issues New Guideline for Drug Approvals | RegASK\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/paraguay-dinavisa-drug-approval-guideline\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/paraguay-dinavisa-drug-approval-guideline\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/dinavisa-paraguay-approves-new-guideline-good-evaluation-practices-marketing-authorization.png\",\"datePublished\":\"2024-12-18T10:51:47+00:00\",\"description\":\"Paraguay\u2019s DINAVISA releases a new guideline for drug approvals, aligning with global standards for safety and efficacy. Read more at RegASK\",\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/regask.com\\\/paraguay-dinavisa-drug-approval-guideline\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/regask.com\\\/paraguay-dinavisa-drug-approval-guideline\\\/#primaryimage\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/dinavisa-paraguay-approves-new-guideline-good-evaluation-practices-marketing-authorization.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/dinavisa-paraguay-approves-new-guideline-good-evaluation-practices-marketing-authorization.png\",\"width\":800,\"height\":600,\"caption\":\"Dinavisa Paraguay Approves New Guideline Good Evaluation Practices Marketing Authorization\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/regask.com\\\/#website\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"name\":\"RegASK\",\"description\":\"Empowering Smarter Regulatory Decisions\",\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/regask.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\",\"name\":\"RegASK\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/RegASK-Logo-Dark-Round.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/RegASK-Logo-Dark-Round.png\",\"width\":401,\"height\":401,\"caption\":\"RegASK\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/RegASKRegulatoryAffairs\\\/\",\"https:\\\/\\\/x.com\\\/ASKRegASK\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/RegASK\\\/\",\"https:\\\/\\\/www.youtube.com\\\/playlist?list=PL6yPC6gFqelkHbOeyUVKjtHOZXZ2LQbJd\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/c2135b6dbdb95b0886564618fe9f4108\",\"name\":\"Amandine Tricou\",\"sameAs\":[\"http:\\\/\\\/www.regask.com\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Paraguay ver\u00f6ffentlicht neue Richtlinien f\u00fcr Arzneimittelzulassungen | RegASK","description":"Paraguays DINAVISA ver\u00f6ffentlicht eine neue Richtlinie f\u00fcr die Arzneimittelzulassung, die sich an globalen Standards f\u00fcr Sicherheit und Wirksamkeit orientiert. Lesen Sie mehr unter RegASK","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/regask.com\/de\/paraguay-dinavisa-arzneimittelzulassungsrichtlinie\/","og_locale":"de_DE","og_type":"article","og_title":"DINAVISA (Paraguay) Approves New Guideline for Good Evaluation Practices for Marketing Authorization","og_description":"Paraguay\u2019s DINAVISA releases a new guideline for drug approvals, aligning with global standards for safety and efficacy. Read more at RegASK","og_url":"https:\/\/regask.com\/de\/paraguay-dinavisa-arzneimittelzulassungsrichtlinie\/","og_site_name":"RegASK","article_publisher":"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","article_published_time":"2024-12-18T10:51:47+00:00","og_image":[{"width":800,"height":600,"url":"https:\/\/regask.com\/wp-content\/uploads\/2024\/12\/dinavisa-paraguay-approves-new-guideline-good-evaluation-practices-marketing-authorization.png","type":"image\/png"}],"author":"Amandine Tricou","twitter_card":"summary_large_image","twitter_creator":"@ASKRegASK","twitter_site":"@ASKRegASK","twitter_misc":{"Written by":"Amandine Tricou","Est. reading time":"2\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/regask.com\/paraguay-dinavisa-drug-approval-guideline\/#article","isPartOf":{"@id":"https:\/\/regask.com\/paraguay-dinavisa-drug-approval-guideline\/"},"author":{"name":"Amandine Tricou","@id":"https:\/\/regask.com\/#\/schema\/person\/c2135b6dbdb95b0886564618fe9f4108"},"headline":"DINAVISA (Paraguay) Approves New Guideline for Good Eva&hellip;","datePublished":"2024-12-18T10:51:47+00:00","mainEntityOfPage":{"@id":"https:\/\/regask.com\/paraguay-dinavisa-drug-approval-guideline\/"},"wordCount":232,"publisher":{"@id":"https:\/\/regask.com\/#organization"},"image":{"@id":"https:\/\/regask.com\/paraguay-dinavisa-drug-approval-guideline\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2024\/12\/dinavisa-paraguay-approves-new-guideline-good-evaluation-practices-marketing-authorization.png","keywords":["Market authorization regs","Guideline"],"articleSection":["Pharma and Biotech","Paraguay"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/regask.com\/paraguay-dinavisa-drug-approval-guideline\/","url":"https:\/\/regask.com\/paraguay-dinavisa-drug-approval-guideline\/","name":"Paraguay ver\u00f6ffentlicht neue Richtlinien f\u00fcr Arzneimittelzulassungen | RegASK","isPartOf":{"@id":"https:\/\/regask.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/regask.com\/paraguay-dinavisa-drug-approval-guideline\/#primaryimage"},"image":{"@id":"https:\/\/regask.com\/paraguay-dinavisa-drug-approval-guideline\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2024\/12\/dinavisa-paraguay-approves-new-guideline-good-evaluation-practices-marketing-authorization.png","datePublished":"2024-12-18T10:51:47+00:00","description":"Paraguays DINAVISA ver\u00f6ffentlicht eine neue Richtlinie f\u00fcr die Arzneimittelzulassung, die sich an globalen Standards f\u00fcr Sicherheit und Wirksamkeit orientiert. Lesen Sie mehr unter RegASK","inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/regask.com\/paraguay-dinavisa-drug-approval-guideline\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/regask.com\/paraguay-dinavisa-drug-approval-guideline\/#primaryimage","url":"https:\/\/regask.com\/wp-content\/uploads\/2024\/12\/dinavisa-paraguay-approves-new-guideline-good-evaluation-practices-marketing-authorization.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2024\/12\/dinavisa-paraguay-approves-new-guideline-good-evaluation-practices-marketing-authorization.png","width":800,"height":600,"caption":"Dinavisa Paraguay Approves New Guideline Good Evaluation Practices Marketing Authorization"},{"@type":"WebSite","@id":"https:\/\/regask.com\/#website","url":"https:\/\/regask.com\/","name":"RegASK","description":"Intelligentere Regulierungsentscheidungen erm\u00f6glichen","publisher":{"@id":"https:\/\/regask.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/regask.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/regask.com\/#organization","name":"RegASK","url":"https:\/\/regask.com\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/regask.com\/#\/schema\/logo\/image\/","url":"https:\/\/regask.com\/wp-content\/uploads\/2024\/10\/RegASK-Logo-Dark-Round.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2024\/10\/RegASK-Logo-Dark-Round.png","width":401,"height":401,"caption":"RegASK"},"image":{"@id":"https:\/\/regask.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","https:\/\/x.com\/ASKRegASK","https:\/\/www.linkedin.com\/company\/RegASK\/","https:\/\/www.youtube.com\/playlist?list=PL6yPC6gFqelkHbOeyUVKjtHOZXZ2LQbJd"]},{"@type":"Person","@id":"https:\/\/regask.com\/#\/schema\/person\/c2135b6dbdb95b0886564618fe9f4108","name":"Amandine Tricou","sameAs":["http:\/\/www.regask.com"]}]}},"_links":{"self":[{"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/posts\/7909","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/users\/30"}],"replies":[{"embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/comments?post=7909"}],"version-history":[{"count":0,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/posts\/7909\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/media\/7926"}],"wp:attachment":[{"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/media?parent=7909"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/categories?post=7909"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/tags?post=7909"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}